Next Article in Journal
Systemic Proteome Alterations Linked to Early Stage Pancreatic Cancer in Diabetic Patients
Previous Article in Journal
Modern Radiotherapy for Pediatric Brain Tumors
Review

A Driver Never Works Alone—Interplay Networks of Mutant p53, MYC, RAS, and Other Universal Oncogenic Drivers in Human Cancer

1
Mossakowski Medical Research Centre Polish Academy of Sciences A. Pawinskiego 5, 02-106 Warsaw, Poland
2
Central Clinical Hospital of the Ministry of the Interior and Administration, Woloska 137, 02-507 Warsaw, Poland
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(6), 1532; https://doi.org/10.3390/cancers12061532
Received: 6 May 2020 / Revised: 3 June 2020 / Accepted: 5 June 2020 / Published: 11 June 2020
(This article belongs to the Section Systematic Review or Meta-Analysis in Cancer Research)
The knowledge accumulating on the occurrence and mechanisms of the activation of oncogenes in human neoplasia necessitates an increasingly detailed understanding of their systemic interactions. None of the known oncogenic drivers work in isolation from the other oncogenic pathways. The cooperation between these pathways is an indispensable element of a multistep carcinogenesis, which apart from inactivation of tumor suppressors, always includes the activation of two or more proto-oncogenes. In this review we focus on representative examples of the interaction of major oncogenic drivers with one another. The drivers are selected according to the following criteria: (1) the highest frequency of known activation in human neoplasia (by mutations or otherwise), (2) activation in a wide range of neoplasia types (universality) and (3) as a part of a distinguishable pathway, (4) being a known cause of phenotypic addiction of neoplastic cells and thus a promising therapeutic target. Each of these universal oncogenic factors—mutant p53, KRAS and CMYC proteins, telomerase ribonucleoprotein, proteasome machinery, HSP molecular chaperones, NF-κB and WNT pathways, AP-1 and YAP/TAZ transcription factors and non-coding RNAs—has a vast network of molecular interrelations and common partners. Understanding this network allows for the hunt for novel therapeutic targets and protocols to counteract drug resistance in a clinical neoplasia treatment. View Full-Text
Keywords: cancer; oncogene; transformation; mutant p53; MYC; RAS cancer; oncogene; transformation; mutant p53; MYC; RAS
Show Figures

Figure 1

MDPI and ACS Style

Grzes, M.; Oron, M.; Staszczak, Z.; Jaiswar, A.; Nowak-Niezgoda, M.; Walerych, D. A Driver Never Works Alone—Interplay Networks of Mutant p53, MYC, RAS, and Other Universal Oncogenic Drivers in Human Cancer. Cancers 2020, 12, 1532. https://doi.org/10.3390/cancers12061532

AMA Style

Grzes M, Oron M, Staszczak Z, Jaiswar A, Nowak-Niezgoda M, Walerych D. A Driver Never Works Alone—Interplay Networks of Mutant p53, MYC, RAS, and Other Universal Oncogenic Drivers in Human Cancer. Cancers. 2020; 12(6):1532. https://doi.org/10.3390/cancers12061532

Chicago/Turabian Style

Grzes, Maria, Magdalena Oron, Zuzanna Staszczak, Akanksha Jaiswar, Magdalena Nowak-Niezgoda, and Dawid Walerych. 2020. "A Driver Never Works Alone—Interplay Networks of Mutant p53, MYC, RAS, and Other Universal Oncogenic Drivers in Human Cancer" Cancers 12, no. 6: 1532. https://doi.org/10.3390/cancers12061532

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop